WO2014042261A1 - サーチュイン遺伝子活性増強剤ならびにそれを用いた医薬品、化粧品、および食品 - Google Patents
サーチュイン遺伝子活性増強剤ならびにそれを用いた医薬品、化粧品、および食品 Download PDFInfo
- Publication number
- WO2014042261A1 WO2014042261A1 PCT/JP2013/074939 JP2013074939W WO2014042261A1 WO 2014042261 A1 WO2014042261 A1 WO 2014042261A1 JP 2013074939 W JP2013074939 W JP 2013074939W WO 2014042261 A1 WO2014042261 A1 WO 2014042261A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sirtuin gene
- plant
- terpenoid
- polyphenol
- gene activity
- Prior art date
Links
- 108050002485 Sirtuin Proteins 0.000 title claims abstract description 62
- 235000013305 food Nutrition 0.000 title claims abstract description 33
- 239000002537 cosmetic Substances 0.000 title claims abstract description 15
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract description 4
- 229940127557 pharmaceutical product Drugs 0.000 title abstract description 4
- 230000000694 effects Effects 0.000 claims abstract description 70
- 241000196324 Embryophyta Species 0.000 claims abstract description 50
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 44
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 44
- 150000003505 terpenes Chemical class 0.000 claims abstract description 41
- 239000000419 plant extract Substances 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 235000014360 Punica granatum Nutrition 0.000 claims abstract description 10
- 241000219991 Lythraceae Species 0.000 claims abstract 2
- 239000003623 enhancer Substances 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 37
- 239000000126 substance Substances 0.000 claims description 25
- RIUPLDUFZCXCHM-UHFFFAOYSA-N Urolithin A Chemical compound OC1=CC=C2C3=CC=C(O)C=C3OC(=O)C2=C1 RIUPLDUFZCXCHM-UHFFFAOYSA-N 0.000 claims description 24
- BYXCFUMGEBZDDI-UHFFFAOYSA-N 1,3,7-trimethyluric acid Chemical compound CN1C(=O)N(C)C(=O)C2=C1NC(=O)N2C BYXCFUMGEBZDDI-UHFFFAOYSA-N 0.000 claims description 14
- SSIRGMIVWUBXFB-UHFFFAOYSA-N punicalin Natural products OC1OC2COC(=O)c3cc(O)c(O)c(O)c3c4c(O)c(O)c5OC(=O)c6c(c(O)c(O)c7OC(=O)c4c5c67)c8cc(C(=O)OC2C(O)C1O)c(O)c(O)c8O SSIRGMIVWUBXFB-UHFFFAOYSA-N 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 229920000241 Punicalagin Polymers 0.000 claims description 11
- 229940109529 pomegranate extract Drugs 0.000 claims description 11
- ZJVUMAFASBFUBG-OGJBWQGYSA-N punicalagin Chemical compound C([C@H]1O[C@@H]([C@@H]2OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)O[C@H]2[C@@H]1OC(=O)C1=CC(O)=C(O)C(O)=C11)O)OC(=O)C2=CC(O)=C(O)C(O)=C2C2=C(O)C(O)=C(OC3=O)C4=C2C(=O)OC2=C4C3=C1C(O)=C2O ZJVUMAFASBFUBG-OGJBWQGYSA-N 0.000 claims description 11
- LMIBIMUSUFYFJN-RSVYENFWSA-N punicalagin Natural products O[C@@H]1O[C@@H]2COC(=O)c3cc(O)c(O)c(O)c3c4c(O)cc5OC(=O)c6c(c(O)c(O)c7OC(=O)c4c5c67)c8c(O)c(O)c(O)cc8C(=O)O[C@H]2[C@@H]9OC(=O)c%10cc(O)c(O)c(O)c%10c%11c(O)c(O)c(O)cc%11C(=O)O[C@@H]19 LMIBIMUSUFYFJN-RSVYENFWSA-N 0.000 claims description 11
- ZRKSVMFLACVUIU-UHFFFAOYSA-N punicalagin isomer Natural products OC1=C(O)C(=C2C3=4)OC(=O)C=4C4=C(O)C(O)=C3OC(=O)C2=C1C1=C(O)C(O)=C(O)C=C1C(=O)OC1C2OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(O)OC1COC(=O)C1=CC4=C(O)C(O)=C1O ZRKSVMFLACVUIU-UHFFFAOYSA-N 0.000 claims description 11
- 239000004378 Glycyrrhizin Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 9
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 9
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 9
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 9
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 9
- JCGHAEBIBSEQAD-UUUCSUBKSA-N eugeniin Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@@H]3OC(=O)C4=CC(O)=C(O)C(O)=C4C4=C(O)C(O)=C(O)C=C4C(=O)OC[C@H]3O2)OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 JCGHAEBIBSEQAD-UUUCSUBKSA-N 0.000 claims description 8
- 229920001990 Tellimagrandin II Polymers 0.000 claims description 4
- JCGHAEBIBSEQAD-ANGOHYEVSA-N Tellimagrandin II Natural products O=C(O[C@@H]1[C@@H](OC(=O)c2cc(O)c(O)c(O)c2)O[C@@H]2[C@@H]([C@@H]1OC(=O)c1cc(O)c(O)c(O)c1)OC(=O)c1c(c(O)c(O)c(O)c1)-c1c(O)c(O)c(O)cc1C(=O)OC2)c1cc(O)c(O)c(O)c1 JCGHAEBIBSEQAD-ANGOHYEVSA-N 0.000 claims description 4
- 239000000463 material Substances 0.000 abstract description 14
- 210000004027 cell Anatomy 0.000 description 47
- 101000654472 Homo sapiens NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 description 20
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 19
- 239000003814 drug Substances 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000000284 extract Substances 0.000 description 13
- 238000000605 extraction Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- -1 hydrogen halides Chemical class 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 239000000654 additive Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000002708 enhancing effect Effects 0.000 description 9
- 244000294611 Punica granatum Species 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 108010041191 Sirtuin 1 Proteins 0.000 description 7
- 102000000344 Sirtuin 1 Human genes 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- XFYIHRTWDXNCTA-UHFFFAOYSA-N Eugenin Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)OC1CCC2C(C)(CCC3C2(C)CCC4(C)C5CC(C)(C)CCC5(C)CCC34C)C1C XFYIHRTWDXNCTA-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 235000006886 Zingiber officinale Nutrition 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 6
- SUTUBQHKZRNZRA-UHFFFAOYSA-N eugenin Chemical compound O1C(C)=CC(=O)C=2C1=CC(OC)=CC=2O SUTUBQHKZRNZRA-UHFFFAOYSA-N 0.000 description 6
- 235000008397 ginger Nutrition 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 241000234314 Zingiber Species 0.000 description 5
- 235000013353 coffee beverage Nutrition 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 229920001968 ellagitannin Polymers 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 240000007154 Coffea arabica Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 241000219925 Oenothera Species 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 235000008429 bread Nutrition 0.000 description 4
- 235000016213 coffee Nutrition 0.000 description 4
- 235000011990 fisetin Nutrition 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 101000654471 Mus musculus NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 description 3
- 235000004496 Oenothera biennis Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 244000061456 Solanum tuberosum Species 0.000 description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- JMGCAHRKIVCLFW-UHFFFAOYSA-N 1-O-Galloylcastalagin Natural products Oc1cc(cc(O)c1O)C(=O)OC2C3OC(=O)c4c2c(O)c(O)c(O)c4c5c(O)c(O)c(O)c6c5C(=O)OC3C7OC(=O)c8cc(O)c(O)c(O)c8c9c(O)c(O)c(O)cc9C(=O)OCC7OC(=O)c%10cc(O)c(O)c(O)c6%10 JMGCAHRKIVCLFW-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000583531 Alpinia purpurata Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- DNJVYWXIDISQRD-UHFFFAOYSA-N Cafestol Natural products C1CC2(CC3(CO)O)CC3CCC2C2(C)C1C(C=CO1)=C1CC2 DNJVYWXIDISQRD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- 244000004281 Eucalyptus maculata Species 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 244000178231 Rosmarinus officinalis Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241001647091 Saxifraga granulata Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- DNJVYWXIDISQRD-JTSSGKSMSA-N cafestol Chemical compound C([C@H]1C[C@]2(C[C@@]1(CO)O)CC1)C[C@H]2[C@@]2(C)[C@H]1C(C=CO1)=C1CC2 DNJVYWXIDISQRD-JTSSGKSMSA-N 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 235000021186 dishes Nutrition 0.000 description 2
- JMGCAHRKIVCLFW-CNWXVVPTSA-N ellagitannin Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@H]2C3=C4C(=O)O[C@@H]2[C@@H]2[C@@H]5OC(=O)C6=CC(O)=C(O)C(O)=C6C6=C(O)C(O)=C(O)C=C6C(=O)OC[C@H]5OC(=O)C5=CC(O)=C(O)C(O)=C5C=5C(O)=C(O)C(O)=C(C=5C(=O)O2)C4=C(O)C(O)=C3O)=C1 JMGCAHRKIVCLFW-CNWXVVPTSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 235000012015 potatoes Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000021283 resveratrol Nutrition 0.000 description 2
- 229940016667 resveratrol Drugs 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000756137 Hemerocallis Species 0.000 description 1
- 101001013208 Homo sapiens Mediator of RNA polymerase II transcription subunit 15 Proteins 0.000 description 1
- 101000616738 Homo sapiens NAD-dependent protein deacetylase sirtuin-6 Proteins 0.000 description 1
- 101000709248 Homo sapiens NAD-dependent protein deacetylase sirtuin-7 Proteins 0.000 description 1
- 101000616727 Homo sapiens NAD-dependent protein deacylase sirtuin-5, mitochondrial Proteins 0.000 description 1
- 101000863629 Homo sapiens NAD-dependent protein lipoamidase sirtuin-4, mitochondrial Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- JEKMKNDURXDJAD-UHFFFAOYSA-N Kahweol Natural products C1CC2(CC3(CO)O)CC3CCC2C2(C)C1C(C=CO1)=C1C=C2 JEKMKNDURXDJAD-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100029663 Mediator of RNA polymerase II transcription subunit 15 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100030710 NAD-dependent protein deacetylase sirtuin-3, mitochondrial Human genes 0.000 description 1
- 102100021840 NAD-dependent protein deacetylase sirtuin-6 Human genes 0.000 description 1
- 102100034376 NAD-dependent protein deacetylase sirtuin-7 Human genes 0.000 description 1
- 102100021839 NAD-dependent protein deacylase sirtuin-5, mitochondrial Human genes 0.000 description 1
- 102100030709 NAD-dependent protein lipoamidase sirtuin-4, mitochondrial Human genes 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229920000864 Punicalin Polymers 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000109329 Rosa xanthina Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 108091005770 SIRT3 Proteins 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 102000000477 Sirtuin 2 Human genes 0.000 description 1
- 108010041216 Sirtuin 2 Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- XUZYVFYOPRXTRB-UHFFFAOYSA-N Tellimagrandin I Natural products OC1COC(=O)C2=CC(O)=C(O)C(O)=C2C2=C(O)C(O)=C(O)C=C2C(=O)OC1C(C(OC(=O)C=1C=C(O)C(O)=C(O)C=1)C=O)OC(=O)C1=CC(O)=C(O)C(O)=C1 XUZYVFYOPRXTRB-UHFFFAOYSA-N 0.000 description 1
- YKDNTEQLKGYZHT-HTCCRONFSA-N Tellimagrandin I Chemical compound O([C@H]1[C@@H]2OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC[C@H]2OC([C@@H]1OC(=O)C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 YKDNTEQLKGYZHT-HTCCRONFSA-N 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241001261506 Undaria pinnatifida Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 230000000850 deacetylating effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000019225 fermented tea Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 102000056482 human SIRT1 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- JEKMKNDURXDJAD-HWUKTEKMSA-N kahweol Chemical compound C([C@@H]1C[C@]2(C[C@@]1(CO)O)CC1)C[C@H]2[C@@]2(C)[C@H]1C(C=CO1)=C1C=C2 JEKMKNDURXDJAD-HWUKTEKMSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013525 pomegranate juice Nutrition 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- IQHIEHIKNWLKFB-ITTSEVFZSA-N pumcalin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1OC(=O)C1=CC(O)=C(O)C(O)=C11)O)O)OC(=O)C2=CC(O)=C(O)C(O)=C2C2=C(O)C(O)=C(OC3=O)C4=C2C(=O)OC2=C4C3=C1C(O)=C2O IQHIEHIKNWLKFB-ITTSEVFZSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- the present invention relates to a sirtuin gene activity enhancer and pharmaceuticals, cosmetics, and foods using the sirtuin gene activity enhancer, and more specifically, a sirtuin gene activity enhancer that is easy to obtain and has few side effects on the human body, and uses the same Related to pharmaceuticals, cosmetics and food.
- SIRT1-7 are known as mammalian homologues of yeast Sir2, and SIRT1 is particularly involved in the control of fat mobilization, inhibition of neuronal axonal degeneration, insulin secretion from ⁇ cells, gluconeogenesis in the liver, etc. It is thought that life extension is realized through control.
- Patent Document 1 lactic acid bacteria or lactic acid bacteria-derived components
- An object of the present invention is to solve the above problems, and the object of the present invention is to obtain a sirtuin gene activity enhancer that can be obtained from familiar materials and has excellent enhancing activity, and the same It is to obtain pharmaceuticals, cosmetics and food.
- the present invention provides a sirtuin gene activity enhancer containing polyphenol as an active ingredient.
- the polyphenol is at least one compound selected from the group consisting of punicalin, punicalagin, urolithin A, eugenin, telimaglandin I, and related substances.
- the present invention also provides a sirtuin gene activity enhancer containing terpenoid as an active ingredient.
- the terpenoid is at least one compound selected from the group consisting of cafestol, caffeol, glycyrrhizin and related substances.
- the polyphenol is contained in the form of a plant or plant extract.
- the plant or plant extract is a pomegranate or pomegranate extract.
- the terpenoid is contained in the form of a plant or plant extract.
- the present invention is also a pharmaceutical composition containing the sirtuin gene activity enhancer.
- the present invention is also a cosmetic composition containing the sirtuin gene activity enhancer.
- the present invention also relates to a food composition containing an isolated polyphenol and / or terpenoid, wherein the polyphenol is composed of punicalin, punicaladine, urolithin A, eugeniin, terimalangin I, and related substances.
- sirtuin gene activity enhancer of the present invention is obtained from familiar materials, and concerns such as side effects on the human body are avoided in advance.
- the sirtuin gene activity enhancer of the present invention contains plants and / or plant-derived components as active ingredients.
- sirtuin gene refers to, for example, a homolog of Sir2 having a NAD-dependent deacetylating activity enzyme that is considered to contribute to the survival of yeast, nematodes, and Drosophila, and SIRT1 in mammals, Includes SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, and SIRT7.
- the “sirtuin gene activity enhancer” includes a substance alone that can enhance the activity of the sirtuin gene in vivo and / or in vitro, and a composition containing the substance.
- Examples of such plants in the present invention include pomegranate, Nikkei, barley, kale, carrot, elderflower, tea, rosemary, rose, cherry, ginger, red ginger, black ginger, saxifrage, eucalyptus, evening primrose, coffee, licorice and Herbs such as evening primrose, trees, and combinations thereof.
- the parts of the plant that can be used are not particularly limited, but include, for example, whole grass, flowers, fruits, leaves, seeds, roots, stems, rhizomes, root barks and bark, and those optionally fermented. .
- pomegranate flowers, fruits, leaves and seeds for example, Nikkei root bark and bark, young barley leaves, fermented carrots, fermented tea leaves (for example, oolong tea), rosemary Leaves, rose flowers, berries and seeds, cherry bark, flowers and leaves, ginger rhizomes, red ginger rhizomes, black ginger rhizomes, saxifrage whole grass, eucalyptus leaves and bark, evening primrose leaves, coffee Fruits, daylily roots, and evening primrose plants are preferably used.
- the plant may be either pre-dried or raw (undried).
- a sirtuin gene activity enhancer In view of excellent storage stability as a sirtuin gene activity enhancer and the ability to increase the content of components exhibiting activity in the enhancer, it is preferable to use a previously dried one.
- the plant-derived component in the present invention includes an extract (including both an extract compound alone and an extract mixture such as a liquid, a paste, and a powder) that can be obtained from a plant, and a chemical structure similar to that of the extract compound. Any compound having the formula (eg, chemically synthesized) is included.
- plant-derived components examples include polyphenols and terpenoids, and combinations thereof.
- polyphenols include punicalin, punicalagin, urolithin A, urothein B, eucarbanin B, eugeniin, tellimaofficein I. I) and their related substances, and combinations thereof.
- terpenoids include cafestol, kahweol, glycyrrhizin and their analogs, and combinations thereof.
- the plant-derived component can be obtained, for example, by extracting from a predetermined site of the plant using a method known to those skilled in the art.
- Extraction can be performed, for example, by immersing the plant part in a predetermined extraction solvent.
- the plant may be cut in advance to an appropriate length or crushed, for example, in order to increase extraction efficiency.
- the extraction solvent is not particularly limited, but water (for example, hot water); lower alcohols such as methanol, ethanol, propanol and butanol; polyhydric alcohols such as propylene glycol and butylene glycol; ketones such as acetone and methyl ethyl ketone.
- lower alcohols such as methanol, ethanol, propanol and butanol
- polyhydric alcohols such as propylene glycol and butylene glycol
- ketones such as acetone and methyl ethyl ketone.
- Esters such as methyl acetate and ethyl acetate; linear and cyclic ethers such as tetrahydrofuran and diethyl ether; hydrogen halides such as dichloromethane, chloroform and carbon tetrachloride; hydrocarbons such as hexane, cyclohexane and petroleum ether; Examples thereof include aromatic hydrocarbons such as benzene and toluene; polyethers such as polyethylene glycol; pyridines and the like, and these can be used alone or as a mixture.
- Extraction conditions are not particularly limited.
- the amount of extraction solvent is preferably 1 to 50 times volume / dry mass relative to the plant to be immersed.
- the extraction temperature varies depending on the type of solvent used, but is usually set to a temperature between room temperature and the boiling point of the solvent.
- the extraction time can also vary depending on the type, amount, and extraction temperature of the solvent used. For example, when used at room temperature, it may be 1 to 60 hours, and when used near the boiling point of the solvent, it may be about 1 to 300 minutes.
- single extraction with one type of extraction solvent may be performed, or extraction may be performed multiple times with different types of solvents.
- the plant is allowed to cool to room temperature, for example, and the plant is removed by filtration or centrifugation.
- a crude extract can be obtained.
- the obtained crude extract is then purified and the solvent removed by any means for removing impurities (for example, column chromatography).
- a desired plant-derived component can be obtained from the plant.
- the sirtuin gene activity enhancer of the present invention contains polyphenol (eg, ellagitannin) as an active ingredient.
- polyphenol eg, ellagitannin
- ellagitannins include punicalin, punicalagin, urolithin A, enotein B, eucarbanine B, eugenin, terimaglandin I and related substances (eg, C1-C20 saturated fatty acid esters or unsaturated fatty acid esters), and A combination of them is mentioned.
- Polyphenols can be contained in the form of plants or plant extracts. When the plant itself is used, either whole grass or the above-mentioned predetermined part may be used, and it may be raw or dry matter, or any of these pastes or powders.
- an extract prepared as described above may be used.
- examples of such plants or plant extracts are pomegranate (Punica granatum) or pomegranate extract.
- the pomegranate or pomegranate extract may contain polyphenols such as ellagitannins (eg, punicalin, punicalagin, urolithin A, enotein B, eucarbanin B and related substances).
- Polyphenols such as ellagitannins (eg, punicalin, punicalagin, urolithin A, enotein B, eucarbanine B and related substances) can be contained in the form of pomegranate or pomegranate extract.
- Eugenin and their related substances can be contained in the form of roses or extracts thereof.
- Telimaglandin I and their related substances can be contained in the form of Hermanus or its extract.
- the sirtuin gene activity enhancer of the present invention contains a terpenoid as an active ingredient.
- terpenoids include caffeol, caffeol, glycyrrhizin and related substances (for example, C1-C20 saturated fatty acid ester or unsaturated fatty acid ester), and combinations thereof.
- Polyphenols include plants or plant extracts), as well as combinations thereof.
- Terpenoids can be contained in the form of plants or plant extracts.
- Caffe stall, caffeol and their analogs can be contained in the form of coffee or coffee extract.
- Glycyrrhizin and its related substances can be contained in the form of licorice or licorice extract.
- the sirtuin gene activity enhancer of the present invention is not necessarily limited to either in vivo or in vitro, and can be widely used in general applications aimed at enhancing the activity of a sirtuin gene.
- the sirtuin gene activity enhancer of the present invention may be used as a component of a pharmaceutical composition such as a pharmaceutical product or quasi-drug, as it is or in combination with other pharmaceutical compositions. It may be used as a component of the product as it is or in combination with other cosmetic materials, or may be used as a kind of additive added to food compositions such as health foods or food, livestock or aquaculture As a constituent of a feed composition used in the production field such as fish, it may be used as it is or in combination with other feed materials.
- the sirtuin gene activity enhancer of the present invention may be composed of the plant and / or plant-derived component alone, that is, the plant and / or plant-derived component alone, or the plant and / or plant-derived component As long as it is contained as an active ingredient, it may contain other additives or other ingredients that can be generally used as ingredients constituting the pharmaceutical composition, cosmetic composition, food composition or feed composition. Good.
- the sirtuin gene activity enhancer of the present invention contains the plant and / or plant-derived component and the other additive, the proportion of the plant and / or plant-derived component in the enhancer is not necessarily limited. Based on the total mass of the enhancer, for example, 0.01 mass% to 99.99 mass%, preferably 1 mass% to 90 mass%.
- additives conventionally used in the preparation of pharmaceuticals can be used as the other additives.
- additives include, but are not limited to, pharmaceutically acceptable excipients, binders, disintegrants, lubricants, flavoring agents, coloring agents, coating agents and the like.
- the present invention is also a pharmaceutical composition containing the sirtuin gene activity enhancer.
- the form of the pharmaceutical composition of the present invention is not particularly limited, but is usually processed into various dosage forms described in the Japanese Pharmacopoeia.
- a pharmaceutical composition intended for oral administration tablets, capsules, powders, granules, fine granules, sustained release agents, solutions, syrups, emulsions and the like can be mentioned.
- a pharmaceutical composition intended for parenteral administration injections, ointments, lotions and the like can be mentioned.
- the dose varies depending on various conditions such as the body weight of the subject person and can be appropriately selected by those skilled in the art.
- the content may be 0.1% by mass to 30% by mass.
- additives conventionally used in the preparation of cosmetics can be used as the other additives.
- additives include oils, surfactants, humectants, thickeners, preservatives, fragrances, colorants, and drugs.
- the present invention is also a cosmetic composition containing the sirtuin gene activity enhancer.
- the form of the cosmetic composition of the present invention is not particularly limited, and examples include lotions, emulsions, creams, and powders.
- sirtuin gene activity enhancer of the present invention is used as a constituent of a food composition
- food ingredients that are conventionally used in the food field can be used as the other ingredients.
- Food ingredients such as suspending agents, antioxidants, preservatives, thickeners, sweeteners, flavoring agents, polyvinyl pyrrolidone, and food additives such as crystalline cellulose.
- the present invention is also a food composition containing the sirtuin gene activity enhancer. More preferably, the food composition of the present invention contains polyphenol and / or terpenoid once isolated from the plant as a sirtuin gene activity enhancer.
- isolated means that the components contained in the plant are separated from the plant through operations such as extraction.
- the food composition of this invention does not include the case where the said plant is included in a composition as it is as a structural component regardless of dryness / undriedness.
- the food composition of the present invention contains such an isolated polyphenol and / or terpenoid, a higher concentration of polyphenol that could not be achieved by using the above plant as a food or drink as it is. And / or a terpenoid (sirtuin gene activity enhancer) can be contained in the food composition. As a result, it is possible to provide a food composition that is completely different from conventional food and drink.
- the food composition of the present invention refers to all foods that are usually used for food, and any form may be used.
- the said food composition is not limited to solid food, A drink (for example, liquid drink) may be sufficient.
- the term “food composition” used in the present specification refers to all foods including both those that require chewing and those that do not require ingestion, and are paste-like and solid (tablets, granules) at room temperature. Any form of jelly, liquid, and the like.
- Specific examples of food compositions include sweets such as candy, gummi, cookies and biscuits; syrups; fruits or processed vegetables such as dried fruits and dried vegetables; pickles such as potatoes and kimchi; beef jerky; Livestock or fish products such as hamburger, ham, sausage; noodles such as ramen, udon, soba noodles, pasta, and noodles; breads such as bread, French bread, anpan, beet bread; potatoes such as Daifuku and grassy rice; canned fruits, etc.
- the sirtuin gene activity enhancer of the present invention can increase the activity of a sirtuin gene. For this reason, it can be widely used as a material that achieves or expects a life extension or longevity effect of a living body.
- the hSIRT1 (human SIRT1) promoter region ( ⁇ 1593 to ⁇ 1 bp) was obtained by LA-PCR using human genomic DNA extracted from TIG-1 cells (obtained from the Institute of Aging Medicine, Tohoku University) as a template. Primers were synthesized based on the information of the reported hSIRT1 genomic sequence, and primers (hSIRT1p-AseI (SEQ ID NO: 1), hSIRT1p-NheI (SEQ ID NO: 1) added with recognition sequences of AseI and NheI at both ends. 2)) was synthesized. PCR reaction conditions were 94 ° C. for 1 minute, 98 ° C. for 20 seconds; 68 ° C. for 2 minutes for 34 cycles, and 72 ° C. for 10 minutes for extension reaction. In addition, Takara Shuzo LA-Taq was used for Taq DNA polymerase, and primer synthesis was outsourced to Nippon Easy Tee Co., Ltd.
- the hSIRT1 promoter fragment obtained by LA-PCR was TA cloned into pGEM-T Easy vector (Promega Corporation). In addition, the nucleotide sequence was confirmed by sequencing.
- the hSIRT1 promoter fragment incorporated in pGEM-T Easy vector was excised by digestion with restriction enzymes AseI and NheI, and the CMV promoter of pEGFP-C3 (manufactured by Takara Bio Inc.) was also removed by digestion with AseI and NheI, and inserted into this removed site. As a result, phSIRT1p-EGFP was obtained.
- LIPOFECT AMINE 2000 REAGENT manufactured by LIFE TECHNOLOGIES was used, and the protocol was applied.
- Caco-2 cells human colon cancer-derived cells. Obtained from RIKEN BioResource Center
- phSIRT1p-EGFP 10 ⁇ g
- serum-free OPTI-MEM medium 15 ⁇ L
- 15 ⁇ L of LIPOFECT AMINE Reagent is diluted to 1.5 mL with serum-free OPTI-MEM medium, Incubated for 5 minutes at room temperature.
- the culture medium of Caco-2 cells that had been seeded on the previous day during this period was removed and replaced with 5 mL of serum-free OPTI-MEM medium.
- 1.5 mL of the DNA-LIPOFECT AMINE 2000 mixture was added to each 10 mL dish. After the addition, the mixture was gently shaken to mix DNA-LIPOFECT AMINE and OPTI-MEM. After culturing for 3 hours, the DNA-LIPOFECT AMINE mixed solution was removed and replaced with a culture medium containing serum. Thereafter, the cells were cultured for 21 hours at 37 ° C. in 5% CO 2 /95% air, and replaced with a new culture medium.
- the drug G418 was added to the transfected cells so as to be 70 ⁇ g / mL and subjected to drug selection for 1 week.
- the culture medium was replaced every 3 days, and G418 was added at the same concentration each time. As a result, Caco-2-hSIRT1p-EGFP cells were obtained.
- Example 1 Search for SIRT1-enhanced polyphenol or terpenoid
- Caco-2-hSIRT1p-EGFP cells were used to examine the effect of enhancing the promoter of the sirtuin gene hSIRT1 for various polyphenols or terpenoids.
- Caco-2-hSIRT1p-EGFP cells were seeded in a 96-well plate at 0.6 ⁇ 10 4 cells / well. The next day, 10 ⁇ M polyphenol or terpenoid or control (PBS) was added to each well. Two days after the addition, the culture solution was aspirated, 100 ⁇ L of 4% paraformaldehyde was added to each well, and the mixture was allowed to stand at room temperature for 10 minutes.
- PBS polyphenol or terpenoid or control
- FIG. 1 is a graph showing the effect of various polyphenols or terpenoids on the promoter activity of hSIRT1 when added to Caco-2-hSIRT1p-EGFP cells.
- the vertical axis represents relative hSIRT1 promoter activity, and the higher the value, the stronger the promoter activity.
- the horizontal axis indicates the polyphenol or terpenoid used.
- a particularly strong hSIRT1 promoter enhancing activity was confirmed in punicalin, punicalagin, urolithin A, teriglandin I, eugenin, caffe stall, caffeol, and fisetin.
- Example 2 Confirmation of expression level of endogenous SIRT1 by SIRT1-enhanced polyphenol or terpenoid
- the expression level of the sirtuin gene hSIRT1 in Caco-2 cells after addition of these polyphenols or terpenoids was examined for punicalin, punicalagin, urolithin A, eugenin, caffe stall, caffeol, glycyrrhizin and fisetin. This procedure is shown below.
- Caco-2 cells were seeded in 5 mL dishes at 3.0 ⁇ 10 5 cells, and added to each polyphenol 10 ⁇ M after 24 hours.
- the case without polyphenol and terpenoid treatment was used as a negative control, and 10 ⁇ M resveratrol was added as a positive control. Two days after this treatment, RNA was collected.
- RNA For preparation of total RNA, High® Pure RNA Isolation Kit from Roche (Indianapolis, IN, USA) was used. The reagents and equipment used from the preparation of total RNA to the completion of the reverse transcription reaction were RNase-free. Subconfluent to confluent cells were prepared in a cell culture dish (Greiner bio-one, Monroe, NC, USA). Remove the medium completely, add 400 ⁇ L of cell lysate contained in PBS 200 ⁇ L and High RNA Isolation Kit, and pass the cell lysate well over the entire dish, and 1.5 mL when the cell lysate is no longer viscous Collected into a sample tube. The collected sample was well suspended.
- the filter tube and collection tube included in High® Pure® RNA® Isolation® Kit were assembled, and the sample was pipetted into the buffer receiver at the top of the filter tube and centrifuged at 8,000 ⁇ g for 15 seconds. The liquid discharged to the collection tube was discarded, and the filter tube and this collection tube were assembled again. 90 ⁇ L of DNase incubation buffer per sample was pipetted into a sterilized reaction tube, and 10 ⁇ L of DNase I was added to the tube and mixed. This mixture was pipetted onto the filter tube upper buffer receiver, added to the glass fiber fleece in the filter tube, and incubated at room temperature for 15 minutes.
- Wash buffer I 500 ⁇ L contained in High Pure RNA (Isolation Kit) was added to the buffer tube upper buffer receiver and centrifuged at 8,000 ⁇ g for 15 seconds. The liquid discharged to the collection tube was discarded, and the filter tube and this collection tube were assembled again. Wash buffer II 500 ⁇ L was added to the filter tube upper buffer receiver and centrifuged at 8,000 ⁇ g for 15 seconds. The liquid discharged to the collection tube was discarded, and the filter tube and this collection tube were assembled again. 200 ⁇ L of Wash Buffer II was added to the filter tube upper buffer receiver, and centrifuged at 13,000 ⁇ g for 2 minutes to remove the wash buffer remaining in the filter tube.
- RNA concentration in the solution was calculated based on the absorbance value at 260 nm using a NanoDrop 2000 / 2000c spectrophotometer (Thermo Scientific, Waltham, MA, USA) and used for the subsequent experiments.
- oligo (dT) 20 primer 5 pmol was added to 1.0 ⁇ g of total RNA extracted from the cells, and sterilized water was added so that the total liquid volume became 13 ⁇ L.
- a thermal cycler (Peltier Thermal Cycler PTC-200, MJ Research, Watertown, MA, USA) was subjected to a heat treatment reaction at 65 ° C. for 5 minutes, immediately transferred to ice and rapidly cooled. During that time, the reverse transcriptase reaction program was advanced to the 42 ° C stage and suspended.
- Forward primer (SEQ ID NO: 3) and reverse primer (SEQ ID NO: 4) for hSIRT detection, and forward primer (SEQ ID NO: 5) and reverse primer (SEQ ID NO: 6) for detection of ⁇ -actin as a primer for the calibration curve Each designed. Primer synthesis was outsourced to Takara Bio Inc. (Shiga, Sakai Japan).
- the prepared cDNA was used as a template.
- the cDNA was diluted 1/10 and both forward and reverse primers were diluted to 10 pmol / ⁇ L. Place 51.5 ⁇ L of RNase Free Water, 3.5 ⁇ L of both forward and reverse primers, 0.2 ⁇ L of template cDNA, 7.0 ⁇ L of template cDNA, and 22 ⁇ L of KAPA®SYBR®FAST®qPCR®Kit (NIPPON®Genetics, Tokyo, Japan) into a 0.2 mL PCR tube. Well suspended. Thereafter, 25 ⁇ L was added to each 96-well plate, and quantitative PCR was performed using Thermal Cycle Dicer Real Time System (TaKaRa).
- TaKaRa Thermal Cycle Dicer Real Time System
- the PCR reaction conditions were 95 ° C for 30 seconds for 1 cycle, 95 ° C for 5 seconds, and 60 ° C for 30 seconds for 40 cycles.
- the relative gene expression level of hSIRT was determined by dividing the measured value by the ⁇ -actin value.
- FIG. 2 is a graph showing the expression level of the sirtuin gene hSIRT1 in Caco-2 cells after the addition of various polyphenols or terpenoids.
- the vertical axis shows the relative gene expression level of hSIRT, and the horizontal axis shows the polyphenol or terpenoid used.
- HSIRT1 transcription enhancing effects were observed in all of punicalin, punicalagin, urolithin A, eugenin, caffe stall, caffeol, glycyrrhizin and fisetin.
- Example 3 Search for SIRT1-enhanced plant or plant extract
- the effect of enhancing the promoter of the sirtuin gene hSIRT1 was examined in the same manner as in Example 1 except that various plants or plant extracts of various polyphenols or terpenoids were used.
- FIG. 3 is a graph showing the influence of hSIRT1 on promoter activity when various plants or plant extracts are added to Caco-2-hSIRT1p-EGFP cells.
- the vertical axis represents relative hSIRT1 promoter activity, and the higher the value, the stronger the promoter activity.
- the horizontal axis indicates the plant or plant extract used.
- HaCaT cells human epidermal keratinocyte-derived cell line, distributed by National Center for Child Health and Development, Dr. Taku Miura
- FBS 10% FBS
- 100,000 U / L penicillin Meiji, Tokyo
- 100 mg / L streptomycin Meiji
- the cells were cultured using Dalbecco's Modified Eagle Medium (DMEM) medium (Nissui Pharmaceutical, Tokyo) containing L NaHCO 3 . These cells were subcultured at 37 ° C. in the presence of 5% CO 2 .
- DMEM Dalbecco's Modified Eagle Medium
- a HaCaT cell line (HaCaT-hSIRT1p-EGFP cell) incorporating the vector (phSIRT1-EGFP) described in Reference Example 1 was prepared as follows.
- HaCaT cells were seeded at 9.0 ⁇ 10 5 in a ⁇ 60 mm dish and cultured in DMEM medium containing 10% FBS. Cells as a control were prepared in the same manner. After 24 hours, 8 ⁇ g of phSIRT1p-EGFP was added to and mixed with 300 ⁇ L of DMEM medium, and 24 ⁇ L of transfection reagent Hilymax (Hilymax, Dojin Chemical) was added thereto, and further mixed and incubated at room temperature for 15 minutes. Thereafter, the entire amount was added to HaCaT cells. After 3 hours, the medium was replaced with 10% FBS-containing DMEM medium.
- Example 4 Effect of enhancing promoter of sirtuin gene hSIRT1 by SIRT1-enhancing polyphenol or terpenoid
- HaCaT-hSIRT1p-EGFP cells were plated in a ⁇ 60 mm dish at 1.7 ⁇ 10 6 cells (measured by flow cytometry) or 2.0 ⁇ 10 4 cells / well (measured by IN Cell Analyzer 1000) in a 96-well plate. After 24 hours, Various polyphenols or terpenoids 10 ⁇ M dissolved in DMSO (Wako Pure Chemical Industries) were added.
- FIG. 4 is a graph showing EGFP fluorescence intensity in HaCaT-hSIRT1p-EGFP cells after addition of various polyphenols or terpenoids.
- the vertical axis represents EGFP fluorescence intensity, and the higher the value, the stronger the promoter activity.
- the horizontal axis indicates the polyphenol or terpenoid used.
- punicalin, punicalagin, urolithin A, terrigaglandin, fisetin, caffe stall (derivative) and caffeol the expression effect of hSIRT1 was also observed in skin epidermal cells.
- the obtained fraction was concentrated under reduced pressure, and 5 g of cellulose (Asahi Kasei Avicel) was added to the obtained ethanol-water fraction concentrate as a lyophilization aid and lyophilized. In this way, a powdered pomegranate extract was prepared.
- Example 5 Preparation of tablets
- 10 mg of powdered pomegranate extract of Preparation Example 1 250 g of lactose, 45 g of corn starch and 20 g of carboxymethylcellulose calcium are put in a tumbling granulator, preheated and mixed, and 34 g of an aqueous solution containing 1.7 g of hydroxypropylcellulose is sprayed.
- Grain powder was obtained.
- 100 g of carboxymethylcellulose calcium and 40 g of talc were added and mixed, and the mixed powder was tableted with a tableting machine to obtain a bare tablet.
- Example 6 Production of beverage
- a beverage was prepared based on the following prescription.
- composition ratio (mass ratio) Glycerin 10.0 Powdered pomegranate extract of Preparation Example 1.0 Cellulose 0.1 Citric acid 0.3 Fragrance 0.1 Purified water remaining amount The above ingredients were mixed together and stirred to prepare a beverage.
- Example 7 Preparation of lotion
- the following ingredients were uniformly mixed at the following ratio to obtain a skin lotion.
- composition ratio (mass ratio) Glycerin 10.0 1,3-butylene glycol 6.0 Powdered pomegranate extract of Preparation Example 1.0 Citric acid 0.1 Sodium citrate 0.3 Polyoxyethylene 1.0 Ethyl alcohol 8.0 Paraben 0.1 Fragrance 0.1 Purified water remaining
- sirtuin gene activity enhancer of the present invention is obtained from familiar materials, and concerns such as side effects on the human body are avoided in advance.
- Such a sirtuin gene activity enhancer is useful as a new material in the pharmaceutical, cosmetic and food fields.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Non-Alcoholic Beverages (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
サーチュイン遺伝子活性増強剤の探索に用いるために、サーチュイン遺伝子のプロモーターを導入した細胞を、以下に示すように調製した。
本実施例では、Caco-2-hSIRT1p-EGFP細胞を用いて、種々のポリフェノールまたはテルペノイドについて、サーチュイン遺伝子hSIRT1のプロモーターの増強効果を調べた。
本実施例では、プニカリン、プニカラジン、ウロリチンA、オイゲニイン、カフェストール、カフェオール、グリチルリチンおよびフィセチンについて、これらのポリフェノールまたはテルペノイド添加後のCaco-2細胞におけるサーチュイン遺伝子hSIRT1の発現量を調べた。この手順を以下に示す。
本実施例においては、種々のポリフェノールまたはテルペノイドの種々の植物または植物抽出物を用いたこと以外は、実施例1と同様にして、サーチュイン遺伝子hSIRT1のプロモーターの増強効果を調べた。
サーチュイン遺伝子活性増強剤のSIRT1発現増強効果をさらに検証するために、サーチュイン遺伝子のプロモーターを導入した細胞を、以下に示すように調製した。
HaCaT細胞(ヒト表皮ケラチノサイト由来細胞株、国立成育医療センター・三浦巧博士より分与)は、10% FBS、100,000U/Lペニシリン(Meiji、東京)、100mg/Lストレプトマイシン(Meiji)、2.0g/L NaHCO3を含むDalbecco’s Modified Eagle Medium(DMEM)培地(日水製薬、東京)を用いて培養した。これらの細胞は、37℃、5% CO2存在下で継代培養した。
以下のようにして、参考例1に記載のベクター(phSIRT1-EGFP)を組み込んだHaCaT細胞株(HaCaT-hSIRT1p-EGFP細胞)を作製した。
HaCaT細胞をφ60mmディッシュに9.0×105個播種し、10% FBS含有DMEM培地で培養した。コントロールとしての細胞も同様に用意した。24時間後、phSIRT1p-EGFP 8μgをDMEM培地300μLに加えて混ぜ、そこにトランスフェクション試薬であるハイリーマックス(Hilymax、同仁化学)24μLを加えてさらに混ぜ、15分間室温でインキュベートした。その後、全量をHaCaT細胞へ添加した。3時間後、10% FBS含有DMEM培地に交換した。
遺伝子導入から24時間後、G418(和光純薬)を750μg/mL含む10% FBS含有DMEM培地に交換した。コントロールの無処理HaCaT細胞が全滅するのを顕微鏡下目視にて確認した後、G418を150μg/mLとした10% FBS含有DMEM培地にて継代培養を続けた。
上記継代培養後の細胞にきちんとphSIRT1p-EGFPベクターが入っているかをフローサイトメトリーにより確認した。上記の細胞とコントロールの無処理HaCaT細胞とをφ60mmディッシュに7.0×105個播種した。24時間後、細胞を剥がして5% FBS含有DMEM培地2mLでよく懸濁し、ナイロンメッシュ(共通理工、日本)にかけて、フローサイトメーター(EPICS, BeckmanCoulter)でEGFP蛍光強度の測定を行った。解析ソフトはFlowJo(Tree Star, Ashland OR)を用い、それぞれの細胞のEGFP蛍光強度をヒストグラム化した。
HaCaT-hSIRT1p-EGFP細胞をφ60mmディッシュに1.7×106細胞(フローサイトメトリーによる測定時)または96ウェルプレートに2.0×104細胞/ウェル(IN Cell Analyzer 1000による測定時)撒き、24時間後、DMSO(和光純薬)に溶解させた各種ポリフェノールまたはテルペノイド10μMを添加した。なお、ネガティブコントロールとしてポリフェノールおよびテルペノイド無処理の場合、DMSOを同量添加し、そしてポジティブコントロールとしてレスベラトロール10μMを添加した。各種ポリフェノールまたはテルペノイドまたはコントロール添加から24時間後、フローサイトメトリーにより蛍光強度を測定した。
市販の乾燥ザクロ粉末(果実および種子、中国産)300gに水700mLを加え、50℃にて24時間攪拌放置し、放冷後遠心分離して、抽出液900mLを得た。その抽出液をアンバーライトXAD4(オルガノ社製)100gを充填したカラムに注入し、3000mLの水を流し、その後、エタノール:水=8:1(v:v)混液を1500mL流した。得られた画分を減圧下で濃縮した後、得られたエタノール-水画分濃縮物に凍結乾燥助剤としてセルロース(旭化成アビセル)5gを加え、凍結乾燥した。このようにして、粉末状ザクロ抽出物を調製した。
上記粉末状ザクロ抽出物のエラジタンニン量を、文献(J. Agric. Food Chem., 2009年, 57(16)、p.7395)に記載の下記条件に従い、HPLC(型番Inertsil ODS-3、ジーエルサイエンス株式会社製)で定量した。
検出器:紫外吸光光度計(380nm)
カラム:Inertsil ODS-3(5μm、4.6×250mm)(ジーエルサイエンス株式会社製)
カラム温度:40℃
流量:1.0mL/分
注入量:25μL
移動相条件:0.5%リン酸(A)およびアセトニトリル(B)を、以下の条件でリニアグラジエントを行った:
A B
0分 95% 5%
10分 85% 15%
30分 75% 25%
35分 95% 5%
プニカリン 25%
プニカラジン 30%
エノテインB 0.1%
調製例1の粉末状ザクロ抽出物10mg、乳糖250g、コーンスターチ45gおよびカルボキシメチルセルロースカルシウム20gを転動造粒機に入れ、予熱混合し、ヒドロキシプロピルセルロース1.7gを含む水溶液34gをスプレーして、造粒末を得た。ここにカルボキシメチルセルロースカルシウム100gおよびタルク40gを加えて混合し、この混合末を打錠機により打錠し、裸錠を得た。
下記処方に基づき、飲料を作成した。
グリセリン 10.0
調製例1の粉末状ザクロ抽出物 1.0
セルロース 0.1
クエン酸 0.3
香料 0.1
精製水 残量
上記各成分を一緒に混合し、撹拌することにより飲料を作製した。
以下の成分を以下の割合で均一に混合して化粧水を得た。
グリセリン 10.0
1,3-ブチレングリコール 6.0
調製例1の粉末状ザクロ抽出物 1.0
クエン酸 0.1
クエン酸ナトリウム 0.3
ポリオキシエチレン 1.0
エチルアルコール 8.0
パラベン 0.1
香料 0.1
精製水 残量
Claims (8)
- ポリフェノールを有効成分として含有するサーチュイン遺伝子活性増強剤であって、該ポリフェノールが、プニカリン、プニカラジン、ウロリチンA、オイゲニイン、テリマグランジンIおよびそれらの類縁物質からなる群より選択される少なくとも1種の化合物である、サーチュイン遺伝子活性増強剤。
- テルペノイドを有効成分として含有するサーチュイン遺伝子活性増強剤であって、該テルペノイドが、カフェストール、カフェオール、グリチルリチンおよびそれらの類縁物質からなる群から選択される少なくとも1種の化合物である、サーチュイン遺伝子活性増強剤。
- 前記ポリフェノールが、植物または植物抽出物の形態で含有される、請求項1に記載のサーチュイン遺伝子活性増強剤。
- 前記植物または植物抽出物が、ザクロまたはザクロ抽出物である、請求項3に記載のサーチュイン遺伝子活性増強剤。
- 前記テルペノイドが、植物または植物抽出物の形態で含有される、請求項2に記載のサーチュイン遺伝子活性増強剤。
- 請求項1から5のいずれかに記載のサーチュイン遺伝子活性増強剤を含有する、医薬組成物。
- 請求項1から5のいずれかに記載のサーチュイン遺伝子活性増強剤を含有する、化粧料組成物。
- 単離されたポリフェノールおよび/またはテルペノイドを含有する、食品組成物であって、
該ポリフェノールが、プニカリン、プニカラジン、ウロリチンA、オイゲニイン、テリマグランジンIおよびそれらの類縁物質からなる群より選択される少なくとも1種の化合物であり、そして
該テルペノイドが、カフェストール、カフェオール、グリチルリチンおよびそれらの類縁物質からなる群から選択される少なくとも1種の化合物である、食品組成物。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/427,312 US20150231164A1 (en) | 2012-09-13 | 2013-09-13 | Sirtuin gene potentiator, and pharmaceutical product, cosmetic product, and food product using same |
CN201380047811.0A CN104703615A (zh) | 2012-09-13 | 2013-09-13 | 沉默调节蛋白基因活性增强剂以及使用其的医药品、化妆品及食品 |
JP2014535612A JPWO2014042261A1 (ja) | 2012-09-13 | 2013-09-13 | サーチュイン遺伝子活性増強剤ならびにそれを用いた医薬品、化粧品、および食品 |
US15/628,684 US20170296568A1 (en) | 2012-09-13 | 2017-06-21 | Sirtuin gene potentiator, and pharmaceutical product, cosmetic product, and food product using same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012201899 | 2012-09-13 | ||
JP2012-201899 | 2012-09-13 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/427,312 A-371-Of-International US20150231164A1 (en) | 2012-09-13 | 2013-09-13 | Sirtuin gene potentiator, and pharmaceutical product, cosmetic product, and food product using same |
US15/628,684 Continuation US20170296568A1 (en) | 2012-09-13 | 2017-06-21 | Sirtuin gene potentiator, and pharmaceutical product, cosmetic product, and food product using same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014042261A1 true WO2014042261A1 (ja) | 2014-03-20 |
Family
ID=50278366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/074939 WO2014042261A1 (ja) | 2012-09-13 | 2013-09-13 | サーチュイン遺伝子活性増強剤ならびにそれを用いた医薬品、化粧品、および食品 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20150231164A1 (ja) |
JP (1) | JPWO2014042261A1 (ja) |
CN (1) | CN104703615A (ja) |
WO (1) | WO2014042261A1 (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015178385A1 (ja) * | 2014-05-19 | 2015-11-26 | サントリーホールディングス株式会社 | バラ色素化合物の新規な用途 |
JP2016216443A (ja) * | 2015-05-15 | 2016-12-22 | 公立大学法人岡山県立大学 | ウロリチン類を含有する育毛剤、及び、ウロリチン類を含有する5αレダクターゼ活性阻害剤 |
JP2017014154A (ja) * | 2015-07-01 | 2017-01-19 | 公立大学法人岡山県立大学 | ウロリチン類を含有するヒアルロン酸産生促進剤 |
JP2017105777A (ja) * | 2015-12-08 | 2017-06-15 | エルジー ハウスホールド アンド ヘルスケア リミテッド | 皮膚改善用組成物 |
JP2017218434A (ja) * | 2016-06-09 | 2017-12-14 | 株式会社ダイセル | ウロリチン類含有水溶液、その乾燥固形組成物、および、それらの製造方法、ならびにウロリチン類の安定化方法および水溶化方法 |
JP2019505504A (ja) * | 2015-12-24 | 2019-02-28 | アマゼンティス エスアーAmazentis Sa | ニコチンアミドリボシド及びウロリチンを含む組成物 |
JP2019097566A (ja) * | 2017-12-07 | 2019-06-24 | 大正製薬株式会社 | 体内時計調整用組成物 |
JP2020189802A (ja) * | 2019-05-22 | 2020-11-26 | 株式会社ブルーム・クラシック | サーチュイン1活性化剤及びサーチュイン1活性化用皮膚化粧料 |
JP2021187789A (ja) * | 2020-06-01 | 2021-12-13 | 株式会社リアルメイト | ヒートショックプロテイン誘導剤、一酸化窒素産生促進剤、抗更年期障害剤、抗加齢剤、化粧品および食品または飲料 |
WO2022114152A1 (ja) * | 2020-11-26 | 2022-06-02 | 株式会社ダイセル | サーチュイン6活性化剤 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3466407A4 (en) * | 2016-05-24 | 2020-07-22 | Natura Cosméticos S.A. | COMPOSITION FOR MODULATING THE GENES RESPONSIBLE FOR GENERAL SKIN FUNCTIONS, METHOD FOR MODULATING THE EXPRESSION OF GENES RESPONSIBLE FOR GENERAL SKIN FUNCTIONS AND USE OF A VEGETABLE EXTRACT |
CN107227269B (zh) * | 2017-05-28 | 2021-05-18 | 广州弘宝元生物科技有限公司 | 具有头孢抗性且高表达Sir2蛋白的嗜酸乳杆菌及其应用 |
CN109316478A (zh) * | 2018-11-06 | 2019-02-12 | 上海出入境检验检疫局动植物与食品检验检疫技术中心 | 一种尿石素a在制备抗衰老的药物、化妆品中的应用及药物、化妆品 |
CN112807320A (zh) * | 2021-01-25 | 2021-05-18 | 中国农业大学 | 月见草素b作为sirt3激活剂在制备抗皮肤光损伤药物中的应用 |
CN115501222B (zh) * | 2022-09-23 | 2023-08-04 | 同济大学 | 杜鹃素促进体细胞核移植效率的应用及方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008074747A (ja) * | 2006-09-20 | 2008-04-03 | Noevir Co Ltd | コラーゲン産生促進剤 |
JP2009114146A (ja) * | 2007-11-08 | 2009-05-28 | Maruzen Pharmaceut Co Ltd | トランスグルタミナーゼ−1産生促進剤及びインボルクリン産生促進剤 |
JP2010270012A (ja) * | 2009-05-19 | 2010-12-02 | Pias Arise Kk | サーチュイン1活性化剤、サーチュイン1活性化組成物、並びにそのサーチュイン1活性化剤若しくは活性化組成物を配合した皮膚外用剤、化粧料、食品 |
WO2011011721A2 (en) * | 2009-07-24 | 2011-01-27 | Amazentis Sa | Compounds, compositions and methods for protecting brain health in neurodegenerative disorders |
WO2012088519A2 (en) * | 2010-12-23 | 2012-06-28 | Amazentis Sa | Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6716437B1 (en) * | 1993-09-13 | 2004-04-06 | E-L Management Corporation | Topical composition and method for enhancing lipid barrier synthesis |
WO1998027970A2 (en) * | 1996-12-24 | 1998-07-02 | National Research Council Of Canada | Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals |
ES2543981T3 (es) * | 2004-03-24 | 2015-08-26 | The Regents Of The University Of California | Purificaciones de elagitaninos |
US20140349953A1 (en) * | 2011-12-27 | 2014-11-27 | Morishita Jintan Co., Ltd. | Maillard reaction inhibitor |
-
2013
- 2013-09-13 JP JP2014535612A patent/JPWO2014042261A1/ja active Pending
- 2013-09-13 US US14/427,312 patent/US20150231164A1/en not_active Abandoned
- 2013-09-13 WO PCT/JP2013/074939 patent/WO2014042261A1/ja active Application Filing
- 2013-09-13 CN CN201380047811.0A patent/CN104703615A/zh active Pending
-
2017
- 2017-06-21 US US15/628,684 patent/US20170296568A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008074747A (ja) * | 2006-09-20 | 2008-04-03 | Noevir Co Ltd | コラーゲン産生促進剤 |
JP2009114146A (ja) * | 2007-11-08 | 2009-05-28 | Maruzen Pharmaceut Co Ltd | トランスグルタミナーゼ−1産生促進剤及びインボルクリン産生促進剤 |
JP2010270012A (ja) * | 2009-05-19 | 2010-12-02 | Pias Arise Kk | サーチュイン1活性化剤、サーチュイン1活性化組成物、並びにそのサーチュイン1活性化剤若しくは活性化組成物を配合した皮膚外用剤、化粧料、食品 |
WO2011011721A2 (en) * | 2009-07-24 | 2011-01-27 | Amazentis Sa | Compounds, compositions and methods for protecting brain health in neurodegenerative disorders |
WO2012088519A2 (en) * | 2010-12-23 | 2012-06-28 | Amazentis Sa | Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders |
Non-Patent Citations (2)
Title |
---|
DOHOON KIM ET AL.: "SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis", EMBO J., vol. 26, no. 13, 2007, pages 3169 - 3179 * |
KIEN TRINH ET AL.: "Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson's disease through an NRF2-dependent mechanism", J NEUROSCI., vol. 30, no. 16, 2010, pages 5525 - 5532 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020007363A (ja) * | 2014-05-19 | 2020-01-16 | サントリーホールディングス株式会社 | バラ色素化合物の新規な用途 |
JPWO2015178385A1 (ja) * | 2014-05-19 | 2017-04-20 | サントリーホールディングス株式会社 | バラ色素化合物の新規な用途 |
WO2015178385A1 (ja) * | 2014-05-19 | 2015-11-26 | サントリーホールディングス株式会社 | バラ色素化合物の新規な用途 |
JP2016216443A (ja) * | 2015-05-15 | 2016-12-22 | 公立大学法人岡山県立大学 | ウロリチン類を含有する育毛剤、及び、ウロリチン類を含有する5αレダクターゼ活性阻害剤 |
JP2017014154A (ja) * | 2015-07-01 | 2017-01-19 | 公立大学法人岡山県立大学 | ウロリチン類を含有するヒアルロン酸産生促進剤 |
JP2017105777A (ja) * | 2015-12-08 | 2017-06-15 | エルジー ハウスホールド アンド ヘルスケア リミテッド | 皮膚改善用組成物 |
JP2019059761A (ja) * | 2015-12-08 | 2019-04-18 | エルジー ハウスホールド アンド ヘルスケア リミテッド | 皮膚改善用組成物 |
JP7182837B2 (ja) | 2015-12-24 | 2022-12-05 | アマゼンティス エスアー | ニコチンアミドリボシド及びウロリチンを含む組成物 |
JP2019505504A (ja) * | 2015-12-24 | 2019-02-28 | アマゼンティス エスアーAmazentis Sa | ニコチンアミドリボシド及びウロリチンを含む組成物 |
JP2017218434A (ja) * | 2016-06-09 | 2017-12-14 | 株式会社ダイセル | ウロリチン類含有水溶液、その乾燥固形組成物、および、それらの製造方法、ならびにウロリチン類の安定化方法および水溶化方法 |
JP2019097566A (ja) * | 2017-12-07 | 2019-06-24 | 大正製薬株式会社 | 体内時計調整用組成物 |
JP2020189802A (ja) * | 2019-05-22 | 2020-11-26 | 株式会社ブルーム・クラシック | サーチュイン1活性化剤及びサーチュイン1活性化用皮膚化粧料 |
JP7301347B2 (ja) | 2019-05-22 | 2023-07-03 | 株式会社ブルーム・クラシック | サーチュイン1活性化剤及びサーチュイン1活性化用皮膚化粧料 |
JP2021187789A (ja) * | 2020-06-01 | 2021-12-13 | 株式会社リアルメイト | ヒートショックプロテイン誘導剤、一酸化窒素産生促進剤、抗更年期障害剤、抗加齢剤、化粧品および食品または飲料 |
WO2022114152A1 (ja) * | 2020-11-26 | 2022-06-02 | 株式会社ダイセル | サーチュイン6活性化剤 |
Also Published As
Publication number | Publication date |
---|---|
US20150231164A1 (en) | 2015-08-20 |
CN104703615A (zh) | 2015-06-10 |
JPWO2014042261A1 (ja) | 2016-08-18 |
US20170296568A1 (en) | 2017-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014042261A1 (ja) | サーチュイン遺伝子活性増強剤ならびにそれを用いた医薬品、化粧品、および食品 | |
KR101767244B1 (ko) | 길경 추출물을 함유하는 근육 질환 예방 및 치료용 또는 근 기능 개선용 조성물 | |
KR101832897B1 (ko) | 모루신, 구와논 지 또는 상백피를 함유하는 근육 질환 예방 및 치료용 또는 근 기능 개선용 조성물 | |
US20200000867A1 (en) | Composition for inhibiting and preventing myopathy, containing bean leaf extract as active ingredient | |
KR101026528B1 (ko) | 해조류 추출물을 유효성분으로 함유하는 염증성 질환 예방또는 치료용 조성물 | |
KR101806783B1 (ko) | 우엉의 초음파 추출물 및 이의 추출방법 | |
KR101368723B1 (ko) | 비만 예방 및 치료용 조성물과 기능성 식품 | |
JP2010037255A (ja) | 視機能低下予防又は改善剤 | |
KR102241169B1 (ko) | 두메부추 추출물을 포함하는 간 섬유화 또는 간경화 예방, 개선 또는 치료용 조성물 | |
JP2021109861A (ja) | サーチュイン1活性化剤及びサーチュイン1活性化用皮膚化粧料 | |
KR100842054B1 (ko) | 구운감초 추출물 또는 이로부터 분리한 화합물을 포함하는혈당 강하용 조성물 | |
KR102573074B1 (ko) | 시르투인1 활성화제 및 시르투인1 활성화용 피부 화장료 | |
JP2009249331A (ja) | 植物由来の高脂血症の予防または改善剤 | |
KR20150037774A (ko) | 항산화 효능이 증가된 정향의 제조방법 | |
KR101622032B1 (ko) | 심비디움 추출물을 유효성분으로 함유하는 근위축 예방 또는 치료용 약학 조성물 | |
KR20130112980A (ko) | 크레이스토카릭스 오페르쿠라투스 추출물 및 이로부터 분리된 화합물을 유효성분으로 포함하는 동맥경화증의 예방 또는 치료용 조성물 | |
KR102626559B1 (ko) | 금화규 추출물을 유효성분으로 포함하는 면역증진용 조성물 | |
KR102556835B1 (ko) | 어수리 추출물을 유효성분으로 포함하는 면역증진 및 항비만용 조성물 | |
KR102076808B1 (ko) | 갈조류 추출물을 유효성분으로 포함하는 항산화 또는 항염증 조성물 | |
KR102678647B1 (ko) | 블루베리로부터 비니페린 및 테로스틸벤을 대량생산하는 방법 | |
JP7201164B2 (ja) | Keap1-Nrf2システムによる生体防御遺伝子発現の活性化用剤 | |
JP2016069355A (ja) | 骨代謝改善剤 | |
JP6673864B2 (ja) | 終末糖化産物生成抑制剤 | |
KR20240040848A (ko) | 붓순나무 추출물을 함유하는 항바이러스용 조성물 | |
KR20160045895A (ko) | 시계 유전자의 발현량 조정제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13836677 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014535612 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14427312 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13836677 Country of ref document: EP Kind code of ref document: A1 |